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INTRODUCTION
Despite modern immunosuppression, ongoing kidney 
injury and graft loss due to alloantibody-induced immu-
nity remains an important issue.1-4 Driving this response 
are polymorphic HLA antigens. While the impact of 
antibodies to HLA on kidney allograft survival has been 
known for some time, only recently, with the advent of 
sensitive solid-phase assays to detect donor-specific anti-
HLA antibodies (DSA) and the development of the Banff 
diagnostic criteria for antibody-mediated rejection (AMR), 
has the size of the problem been realized. By 10 years, after 
kidney transplant, up to 25% have developed de novo 
DSA (dnDSA).5 Thus, it is not surprising that AMR was 
the most common cause of allograft failure in a cohort of 
Review
Abstract. With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histo-
logical classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of 
kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The 
number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard 
for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society 
convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and 
chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be 
evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes 
were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of 
care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are 
to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive 
evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. 
It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed 
to improve patient outcomes.
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renal transplant recipients with indication biopsies before 
graft failure.3 Moreover, in a multicenter cohort study, 
antibody-mediated damage caused allograft dysfunction 
late posttransplant in nearly 60% of renal transplant 
recipients.4
Given the scope and severity of the problem, it is 
unfortunate that there are no commonly accepted guide-
lines for treatment. To date, clinical trials of AMR have 
been small or inconclusive, and there are no Federal 
Drug Administration (FDA)-approved therapies for the 
prevention and treatment of the condition.6 The lack of 
an accepted common standard for the treatment of AMR 
has been an impediment to the development of new ther-
apies because it is difficult for industry to initiate phase 
2 and 3 clinical trials for novel treatments or preven-
tion of AMR. To overcome this lack of evidence-based 
guidelines, The Transplantation Society brought together 
a group of experts from around the globe for a 1.5-day 
meeting, with the aim of producing a consensus docu-
ment that outlined recommended treatments for active 
and chronic active AMR, based on the best available evi-
dence. This publication is a summary of that meeting and 
includes up-to-date information about the pathogenesis 
of the condition, the criteria for diagnosis, prognosis, and 
long-term outcome.
BIOLOGY OF THE ALLOIMMUNE RESPONSE
A general appreciation of the complex immunologic 
processes underlying antibody production in immuno-
logically naive and presensitized individuals is central to 
understanding the varied presentations of AMR and poten-
tial treatment options (Figure 1). In alloimmune naive indi-
viduals, the generation of antibody-secreting cells follows 
a scripted series of checkpoint events, starting with the 
initial encounter of alloantigen with B cells expressing the 
appropriate B-cell antigen receptor. This event activates 
B-cell migration to the T- and B-cell interface in the lymph 
node, where it receives help from alloreactive T cells that 
encountered alloantigen presented indirectly on recipient 
dendritic cells. Some of B cells differentiate into memory 
B cells or short-lived plasmablasts, while the rest enter 
into germinal centers to emerge as high-affinity and class-
switched memory B cells, plasmablasts, and long-lived 
plasma cells.7,8 In the context of transplantation, presen-
sitized individuals have a robust long-lived plasma cells 
constitutively secreting anti-HLA antibodies and resting 
memory B cells primed to secrete large amounts of anti-
body upon antigen reexposure leading to a rapid anamnes-
tic antibody response.
Some features of the alloimmune response complicate 
our understanding of DSA production, limiting our ability 
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to predict and develop therapeutic approaches for AMR. In 
general, memory B cells are derived from B cells with recep-
tors that are less mutated and of lower affinity than those 
that are destined to become plasma cells.9-11 As a result, the 
repertoire of plasma cells and memory B cells are not iden-
tical. Furthermore, the repertoire of plasma cells and the 
antibodies they produce are up to 100-fold more restricted 
compared with the repertoire of memory B cells.12 These 
differences between memory B cells and plasma cell genera-
tion predict that treatment aiming to prevent plasma cell 
generation and subsequent DSA production may not stop 
the generation of memory B cells. Likewise, the absence of 
DSA does not imply the lack of memory B cells and the 
potential for an anamnestic response. Thus, the ability to 
quantify donor-specific memory B cells may aid in risk 
stratification and treatment of presensitized recipients sus-
ceptible for an active AMR early posttransplant.
The diversity at the level of antibodies presents an 
additional challenge. Antibodies have different Fc regions 
corresponding to their isotype and subclasses, each with 
nonoverlapping functions including their ability to bind 
to Fc receptors and activate complement. Less appreci-
ated is heterogeneity in the anti-HLA antibody repertoire, 
which comprise antibodies that bind to private specifici-
ties on HLA molecules and thus are highly donor specific. 
Alternatively, cross-reactive alloantibodies may be donor 
reactive but not donor specific, and some may bind mul-
tiple HLA molecules. As a result, the breadth of the circu-
lating antibody with HLA reactivity may not be a direct 
readout of the plasma cell repertoire.
DIAGNOSTIC CRITERIA AND HISTOLOGICAL 
FEATURES OF AMR
AMR is a clinicopathological diagnosis that was 
first formally described in a 2003 addition to the 1997 
International Banff Classification of kidney allograft rejec-
tion13 but has continually evolved with our increased 
understanding of AMR particularly with regards to the 
relevance of C4d-negative AMR and the utility of molecu-
lar diagnostics. The salient features of active AMR based 
on the Banff 2017 classification14 are (1) histological 
evidence of graft injury via microvascular inflammation 
(MVI), intimal or transmural arteritis (v > 0), acute throm-
botic microangiopathy in the absence of any other cause, 
or acute tubular injury in the absence of any other appar-
ent cause; (2) histological evidence of antibody-endothelial 
interactions either by C4d deposition or at least moderate 
MVI; and (3) the presence of circulating DSA, predomi-
nantly anti-HLA antibody (Table 1). Clearly, the main his-
tological manifestation of active AMR in renal allografts is 
MVI in the form of glomerulitis (g) and peritubular capil-
laritis (ptc). The presence of either (g + ptc > 0) satisfies 
criterion 1, and a (g + ptc) sum score of ≥2 also satisfies 
criterion 2. The exception is that peritubular capillari-
tis alone is insufficient for diagnosis in the presence of 
T-cell–mediated rejection (TCMR), including borderline 
rejection. Recurrent or de novo glomerulonephritis must 
be considered as a differential diagnosis, especially in the 
context of glomerulitis and thrombotic microangiopathy. 
To diagnose chronic active AMR, morphological features 
of chronic tissue injury are present in addition to crite-
ria 2 and 3 for active AMR. Signs of chronic tissue injury 
include transplant glomerulopathy (Banff chronic glomer-
ulitis [cg] score > 0), severe peritubular capillary basement 
membrane multilayering on electron microscopy, or new 
arterial intimal fibrosis without another obvious cause.
CLINICAL PHENOTYPES OF AMR
The Banff classification has been a major advancement in 
the field of transplantation to increase the awareness of AMR 
and standardize definitions. However, a classification schema 
based on histological features oversimplifies the complexity 
of AMR. The Banff classification has 3 AMR diagnostic cat-
egories (including chronic AMR with transplant glomeru-
lopathy and current or prior DSA but no MVI or C4d): the 
clinical reality is that AMR is frequently a chronic progres-
sive disease process. This chronic disease process starts with 
the formation of DSA. The DSA may or may not lead to 
active AMR with histological features that often include but 
are not limited to MVI. Moreover, not all active AMR will 
progress to chronic active AMR. Over time, chronic histo-
logical features such as transplant glomerulopathy become 
evident, and eventually, the patient develops allograft dys-
function, proteinuria, and probable allograft loss. Thus, find-
ing an active versus chronic active AMR on the biopsy may 
be more reflective of the timing of the biopsy rather than the 
underlying pathological process itself.
Further complicating the diagnosis and management of 
AMR are various clinical phenotypes. AMR can present 
with abrupt allograft dysfunction early posttransplant but 
can also have an insidious or subclinical onset, presenting 
later posttransplant. Anti-HLA antibody can also be pre-
sent before transplant (preexisting DSA) or develop after 
transplant (dnDSA) in the setting of under-immunosuppres-
sion. In some circumstances, the histological features sug-
gestive of AMR are present, but anti-HLA antibody is not 
detected. Incorporating these clinical features of AMR into 
the current Banff classification while considering the likely 
underlying immunologic mechanisms is critical to appro-
priately guide therapeutic decisions and ultimately design 
FIGURE 1. Kinetics of memory B cells and plasma cell generation relative to the germinal center (GC) reaction following transplantation. 
Following encounter with alloantigen, activated B cells migrate to the T- and B-cell interface and receive T-cell help. Some of the helped 
B cells differentiate into memory B cells or plasma cells, while the rest enter into a germinal center to emerge as high-affinity and class-
switched memory B cells and plasma cells. Memory B cells tend to have low levels of somatic hypermutations and lower B-cell receptor 
(BCR) affinity compared with plasma cells, and cells generated pre-GC tend to be of lower affinity than cells generated post-GC.
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efficient and effective therapeutic clinical trials. Therefore, 
we recommend considering the timing of presentation, and 
type of DSA (preexisting or de novo), in relation to the his-
tological classification as discussed below (Table 2).
Early Posttransplant (<30 Days) Active AMR
In patients who have measurable DSA at the time of 
kidney transplant or who have an immunologic amnes-
tic response due to previous exposure to allo-HLA, active 
AMR can occur within the first 30 days posttransplant. 
The risk of early posttransplant AMR increases with 
growing DSA strength or breadth at the time of transplant 
as determined by DSA mean fluorescence intensity (MFI), 
the degree of flow cytometric crossmatch positivity, and 
the number or breadth of cross-reactive DSA specifici-
ties.15,16 In general, this form of AMR is uncommon, as it 
is common practice to avoid allocating kidneys to patients 
with known preformed DSA, as early posttransplant AMR 
occurs in up to 40% of patients with preformed DSA and 
a positive flow cytometric crossmatch.38,39 This aggres-
sive form of active AMR typically presents with an abrupt 
increase in DSA accompanied by allograft dysfunction 
(increased creatinine and oliguria with or without pro-
teinuria). If not recognized and treated quickly, it can lead 
to cortical necrosis and allograft loss within days. From 
a histological perspective, the criteria for Banff active 
AMR are met and C4d is usually positive.40 There is often 
interstitial hemorrhage, glomerular fibrin thrombi, and 
microvascular coagulative necrosis. With prompt diagno-
sis and treatment, patients can recover allograft function 
and histological features of active AMR frequently resolve 
completely.40,41 In other cases, the histological features of 
active AMR persist and chronic active AMR, allograft dys-
function, and ultimate allograft failure ensues.
Late (>30 Days) Posttransplant AMR With 
Preexisting DSA
While many patients with preexisting DSA do not 
develop an aggressive early AMR as described above, they 
can develop an indolent and progressive form of AMR that 
is usually initially detected on a surveillance biopsy (in the 
setting of stable function) or on a for-cause biopsy for mild 
allograft dysfunction.42,43 Histological findings are depend-
ent on the timing of the biopsy. When detected early, MVI 
in glomeruli and peritubular capillaries is the predominant 
finding and C4d staining may or may not be present. MVI 
tends to persist and is later accompanied by chronic his-
tological features including transplant glomerulopathy and 
peritubular basement membrane multilayering.17,44,45 At 
diagnosis, there is often minimal if any reduction in glomer-
ular filtration rate (GFR) or proteinuria even when mild 
chronic features are present. Overtime, however, the GFR 
declines and the patient becomes proteinuric39 with graft 
failure often occurring several years after transplant.18,21 In 
an observational prospective cohort study of >100 renal 
transplant recipients who underwent surveillance biopsy at 
1 year, patients with AMR were the most likely to experi-
ence allograft failure.21 Allograft survival was only 56% at 
8 years posttransplant compared with 88% if subclinical 
TCMR was present, and 90% if the biopsy was normal.21
Late (>30 Days) AMR Associated With dnDSA
In the current era of sensitive DSA testing and a general 
avoidance of preexisting DSA, the most common form of 
AMR is associated with dnDSA. In general, dnDSA is a new 
DSA detected after >3 months posttransplant in the context of 
inadequate immunosuppression which is either due to patient 
nonadherence, physician directed, or genetically determined 
variability in metabolism of immunosuppressive drugs. This 
TABLE 1.
Banff 2017 classification of AMR in renal allografts14
Active AMR All 3 criteria must be met for diagnosis
1 Histological evidence of acute tissue injury, including 1 or more of the following:
  (a) Microvascular inflammation (g > 0 or ptc > 0), in the absence of recurrent or de novo glomerulonephritis. In the presence 
of acute T-cell–mediated rejection, borderline infiltrate, or infection, ptc >1 alone is not sufficient.
  (b) Intimal or transmural arteritis (v > 0)
  (c) Acute thrombotic microangiopathy, in the absence of any other cause
  (d) Acute tubular injury, in the absence of any other apparent cause
2 Evidence of current/recent antibody interaction with vascular endothelium, including 1 or more the following:
  (a) Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by immunofluorescence on frozen sections, or C4d >0 by IHC 
on paraffin sections)
  (b) At least moderate microvascular inflammation ([g + ptc] ≥2) in the absence of recurrent or de novo glomerulonephritis, 
although in the presence of a T-cell–mediated rejection, borderline infiltrate, or infection, ptc ≥2 alone is not sufficient.
  (c) Increased expression of gene transcripts/classifiers in the biopsy tissue strongly associated with AMR, if thoroughly vali-
dated.
3 Serological evidence of donor-specific antibodies (DSA to HLA or other antigens); C4d staining or expression of validated tran-




Morphological evidence of chronic tissue injury, including 1 or more the following, plus criteria 2 and 3 for Active AMR:
 Transplant glomerulopathy (cg >0) if no evidence of chronic thrombotic microangiopathy or chronic recurrent/de novo glo-
merulonephritis; includes changes evident by electron microscopy alone
  Severe peritubular capillary basement membrane multilayering on electron microscopy
  Arterial intimal fibrosis of new onset, excluding other causes
AMR, antibody-mediated rejection; cg, chronic glomerulitis; DSA, donor-specific antibody; g, glomerulitis; IHC, immunohistochemistry; ptc, peritubular capillaritis; v, vasculitis score.
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form of AMR often presents with allograft dysfunction and 
concomitant or preexisting TCMR.3,46,47 In patients who 
have routine surveillance DSA testing or surveillance biopsies, 
the presentation can be more indolent and is similar to that 
of late posttransplant AMR in patients with preexisting DSA 
(subclinical AMR associated with dnDSA).46
Results from 2 recent studies have suggested that AMR 
with dnDSA is associated with inferior allograft survival 
when compared with AMR from preexisting DSA after 
adjusting for clinical, histological, and immunologic char-
acteristics.19,23 Allograft survival was 63% in patients with 
preexisting DSA and only 34% in patients with dnDSA 
8 years after the rejection diagnosis.19 Despite these find-
ings, it remains unclear whether it is the dnDSA itself that 
is associated with inferior allograft survival or a delay in 
AMR diagnosis. Compared with patients with preexisting 
DSA, those with dnDSA tend to have increased proteinuria 
and increased expression of interferon-γ–inducible, natu-
ral killer cell, and T-cell transcripts at presentation.19
FEATURES ASSOCIATED WITH REDUCED 
ALLOGRAFT SURVIVAL IN LATE AMR 
(PREEXISTING OR DNDSA)
Although there are differences in the initial presentation of 
AMR and pace of clinical deterioration depending on whether 
the DSA is formed before the transplant, or is dnDSA, the his-
tological, clinical, and alloantibody features associated with 
reduced allograft survival are similar (Table  2). Allograft 
histology is key to document the chronicity and extent of 
injury. Chronic histological features such as the presence of 
transplant glomerulopathy (Banff cg score >0)19,21,22 and the 
degree of interstitial fibrosis and tubular atrophy23-25 are pre-
dictive of allograft failure. Other histological features asso-
ciated with inferior allograft survival include concomitant 
TCMR,22-24,26,27 C4d positivity,28-30,48 and vascular lesions 
(Banff cv score >0).24 Not surprisingly, clinical factors are 
also predictive of outcome including allograft dysfunction 
at diagnosis,19,22,24,25,31,49 proteinuria,19,25,31,32 and time of 
diagnosis posttransplant.24,25 To illustrate the relevance of 
having allograft dysfunction at presentation: time to 50% 
graft failure was 3.3 years in patients with allograft dysfunc-
tion versus 8.3 years in patients without allograft dysfunc-
tion among 47 patients with dnDSA.22 Although it is clear 
that under-immunosuppression is a major risk factor for 
dnDSA, prior studies have also shown that a history of medi-
cation nonadherence is independently associated with infe-
rior allograft survival among patients with dnDSA.22,25,50,51
Lastly, several alloantibody characteristics have been 
associated with outcome including the presence of C1q-
positive DSA34,35,52 and anticlass II DSA.17,36 Additionally, 
the level or strength of DSA correlates with graft failure 
as determined by DSA titer or flow cytometric crossmatch 
positivity. Notably, several studies have correlated DSA 
titer and MFI with C1q positivity53; thus, it is unclear 
whether complement binding characteristics or levels of 
alloantibody determine outcomes.
CONSENSUS FOR MEASURING AND MONITORING 
OF DSA
Initial Assessment for Anti-HLA DSA
The initial assessment of a renal transplant candidate 
involves donor and recipient HLA typing, anti-HLA 
antibody screening, and obtaining a history of allosensi-
tizing events (previous transplant, blood transfusion, and 
pregnancy) (strength of recommendations and level of evi-
dence 1A).54-56 Molecular HLA typing ideally includes A; 
B; C; DRB1; DRB3, 4, 5; DQA1/DQB1; and DPA1/DPB1 
(2B). For anti-HLA–sensitized recipients, a high-resolution 
level of typing, approaching or even reaching the allelic 
level (ie, the so-called “4-digit” typing), should be under-
taken as often as possible on the potential donor, to match 
the resolution of the alloantibody identification assays. 
The first-line screening for alloantibody would be with 
single-antigen bead (SAB) solid-phase assays (LABScreen 
[one Lambda] or LifeScreen [LifeCodes-Immucor]), but 
multiantigen beads can also be used (1A). Patients with 
no history of allosensitizing events and with negative anti-
HLA antibody testing using single-antigen or multiantigen 
bead solid-phase assays are at low risk for AMR.
Monitoring for De Novo DSA
Immunosuppression reduction either as a result of non-
adherence or under physician direction is associated with 
development of dnDSA.46,47,51 Monitoring for dnDSA is 
recommended in the following settings: immunosuppres-
sion reduction by physician for any reason, known patient 
medication nonadherence, or at the time of rejection epi-
sode (T cell or antibody mediated) (2B). The presence of 
dnDSA is a general indicator of under-immunosuppression 
and signals the need to reevaluate maintenance immu-
nosuppression. Based on the strong relationship between 
dnDSA, AMR, and graft loss, transplant patients with 
dnDSA should undergo close monitoring of allograft func-
tion19,22,47 (1B). A kidney biopsy is also recommended to 
detect T-cell or AMR (clinically evident or subclinical).6
Interpreting Positive DSA Results
The SAB test detecting DSA has been an important 
advancement to the field; however, the test has limitations 
that must be identified for correct interpretation. First, the 
SAB test has a high coefficient of variation, and thus, the posi-
tive cutoff varies among and within laboratories. In general, 
a positive cutoff MFI of 1000–1500 is associated with the 
detection of specific anti-HLA antibodies.57 SAB tests are also 
prone to interference from external substances, bead satura-
tion, and “shared-epitope” phenomenon, which can lead to a 
falsely low MFI.53,58,59 Methods to identify interference and 
bead saturation include performing serum dilution or using 
ethylenediaminetetraacetic acid. We recommend the routine 
use of these methods in the following situations: transplant 
candidates/recipients who are not immunologically naive, 
unexpected positive crossmatch, or AMR with unexpectedly 
low DSA MFI (2B).
Additional DSA Testing for Risk Stratification
All patients with DSA are at some risk for AMR. 
Crossmatch testing can be used with SAB testing for AMR 
risk stratification. The risks of AMR from highest to low-
est based on crossmatch and SAB-positive testing are the 
following: positive complement-dependent cytotoxicity 
(CDC) crossmatch, positive flow cytometric crossmatch, 
and negative crossmatch.60 Importantly, hyperacute AMR 
is also associated with having a positive CDC crossmatch.
Testing to assess the complement binding ability of DSA 
(C1q or C3d) is commercially available, and positive results 
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are associated with AMR and allograft loss.34,52 However, 
C1q and C3d binding positivity is associated with a high 
DSA titer.53 It remains unclear whether complement bind-
ing assays outperform antibody titers for AMR risk strati-
fication. For this reason, we do not recommend routine use 
of complement binding assays unless it is used as a means 
of predicting high strength DSA. Lastly, DSA IgG subclass 
testing has been used for research purposes. This testing 
has not been thoroughly validated for clinical use and at 
the moment cannot be recommended.
AVAILABLE EVIDENCE FOR THE TREATMENT OF 
ACTIVE AND CHRONIC ACTIVE AMR
Most reports on the treatment of AMR are small and 
include heterogeneous patient populations. These studies 
frequently include mixed antibody and TCMRs, do not dif-
ferentiate responses based on the timing of AMR detection, 
and make no distinction between dnDSA and preformed 
DSA, although all these factors have an impact on out-
come.61 The heterogeneity of available studies makes it diffi-
cult to draw meaningful conclusions about treatment effects. 
As recommended by guidelines,56 most studies describe the 
use of a variable mix of interventions (eg, variable intensity 
of plasmapheresis, different doses of intravenous immune 
globulins [IVIG], variable use of steroid pulses together with 
or without different T-cell–depleting and B-cell–depleting 
antibodies). Obviously, these different interventions create a 
challenge in the interpretation of treatment effects. As a con-
sequence, treatment studies for AMR are rarely comparable, 
and the available evidence is generally of low quality.55,62
Plasma Exchange and IVIG
The primary aims of nearly all therapeutic approaches 
for AMR are removing circulating DSA and reducing DSA 
production. In this sense, the strongholds for contemporary 
treatment of AMR are represented by plasma exchange 
(PLEX) and IVIG, although neither of these have FDA 
approval. This treatment regimen is most commonly used 
to treat active AMR, although frequency, modality, and dos-
ing may vary14,55,56,61,62 (Table  3). On those grounds, the 
expert consensus at the FDA Antibody-Mediated Rejection 
Workshop in 201767 as well as Kidney Disease: Improving 
Global Outcomes (KDIGO) in 201068 was that PLEX and 
IVIG could be regarded as a standard of care for acute active 
AMR, despite the weakness of evidence in support of efficacy. 
In particular, their ability to improve short-term outcomes 
has been demonstrated by several studies,65,66,70,71 while 
their results on long-term effects remain variable, emphasiz-
ing the need for new alternatives or adjunctive therapy for 
the treatment of AMR. In addition, there is a need to better 
define the amount of PLEX and dosing of IVIG.
The rationale for using PLEX and IVIG is to combine 
removal of circulating DSA with immunomodulation of the 
antigraft immune response and in particular modulation 
of the B-cell response. In experimental models, IVIG has 
been shown to inhibit B-cell responses by the Fc portion 
of the Ig binding the Fc fragment of IgG2b receptor on B 
cells, and sialylated IVIG binds CD22, inducing apoptosis 
of mature B cells.72 It also functions as a scavenger of acti-
vated complement.72 While PLEX and IVIG have formed 
the mainstay of treatment for acute active AMR, the evi-
dence consists largely of case series and poorly controlled 
randomized trials. Well-designed clinical trials in this 
area have proven difficult. One of the best-designed trials 
recruited only 10 patients (5 in each arm) and consisted of 
immunoabsorption without IVIG. While all of the patients 
receiving immunoabsorption responded to treatment, the 
trial was ceased at the first interim analysis because of 80% 
graft loss in the control arm, which suggests that immuno-
absorption was beneficial in this setting.71
Complement Inhibitors
Over the last decade, the complement system has 
attracted increasing attention as an important contributor 
to AMR. Hence, several studies have been undertaken to 
evaluate the ability of various complement inhibitors to 
prevent and treat AMR. The main goal of using comple-
ment inhibitors is to avoid the downstream damage to the 
allograft from DSA.
Eculizumab results in terminal complement blockade 
as a monoclonal antibody targeting C5. A single-center 
TABLE 3.
Evidence for use of plasma exchange and intravenous immune globulins as SOC in active AMR
Criterion Evidence Reference
Biological rationale Anti-HLA antibodies activate complement and interact with Fc receptors and endothelium.
Removal of anti-HLA Ab via plasma exchange correlates with better clinical response in kidney 
transplant recipients.
Intravenous immune globulins have pleiotropic effects including neutralization of antibodies/
cytokines/activated components of complement, effects on B cells, T cells, and Fc receptors.
Akiyoshi et al63
Gelfand64
Benefit in clinical  
(observational)  
studies
Humoral rejection treated with PE/IVIG results in improved renal function.






FDA 2017 Public workshop: Antibody removal therapies, generally in combination with low- or 
high-dose IVIG (immunomodulation) form the SOC in many institutions.
KDIGO 2010: Recommendation for PE and IVIG in association with corticosteroids.
Velidedeoglu et al67
Kasiske et al68
Most used combination  
in clinical practice
American Society of Transplantation survey: Most centers utilize a combination of IVIG and plas-
mapheresis for treatment.
The treatment of AMR in kidney transplant recipients: a systematic review.
Burton et al69
Roberts et al55
Ab, antibody; AMR, antibody-mediated rejection; Fc, fragment crystallizable; IVIG, intravenous immune globulins; PE, plasma exchange; FDA, Federal Drug Administration; KDIGO, Kidney Disease: 
Improving Global Outcomes; SOC, standard of care.
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study showed that among patients who received positive 
crossmatch HLA-incompatible transplants, the incidence 
of early active AMR was decreased from approximately 
40% in historical controls to 7% among treated patients. 
Furthermore, 2 multicenter randomized phase 2 trials con-
firmed the protective effect of eculizumab for preventing 
early active AMR in positive crossmatch HLA-incompatible 
living73 and deceased74 donor populations. A single-center 
small case series has also shown that eculizumab has effec-
tiveness in treating early active AMR that occurs within 
the first month posttransplant.40 Despite these promising 
results, long-term follow-up of eculizumab-treated posi-
tive crossmatch patients in a single-center study has shown 
that despite prevention of early active AMR, the long-term 
incidence of chronic AMR and allograft survival is compa-
rable to historical controls.18,45
Proximal complement inhibition has also been studied 
as a therapeutic target. The plasma C1 esterase inhibi-
tors Berinert (CSL Behring) and Cinryze (Takeda/Shire/
ViroPharma) have been tested in 2 pilot studies and indi-
cate a possible improvement in allograft function in kid-
ney recipients with AMR.75,76 An additional clinical trial 
evaluating a C1 esterase inhibitor for the treatment of 
AMR that is resistant to PLEX and IVIG (NCT03221842) 
in renal transplant recipients is ongoing.
Rituximab
Rituximab, a B-cell–depleting agent, was suggested as a 
treatment option by KDIGO guidelines.56 Despite its fre-
quent use,69 the evidence is low and 3 small randomized 
trials have investigated its utility without demonstrating 
a clear benefit.55,62,77 A small study in 20 children inves-
tigated the effect of Rituximab compared with standard 
of care (pulse steroids) in B-cell–rich rejections (of whom 
40% in the control group and 80% in treatment group 
had DSA).78 There were no major differences in outcome, 
and Rituximab had a reasonable safety profile. However, 
small numbers, demographic, and baseline differences as 
well as an unclear AMR definition preclude meaningful 
conclusions. The second trial was a French prospective, 
double-blind, multicenter, randomized study investigating 
38 patients with active AMR in the first year after trans-
plantation. All patients received treatment with steroids, 
IVIG, and PLEX and were randomized to either rituxi-
mab or placebo. There was no difference in any outcome 
parameter, except side effects.79 More recently, there was a 
Spanish prospective, randomized, placebo-controlled, dou-
ble-blinded clinical trial where patients were randomized 
to receive IVIG plus Rituximab or IVIG plus saline infu-
sion. Only 50% enrollment was achieved (25 patients), 
and at 12 months, there were no differences between treat-
ment and control groups in estimated glomerular filtration 
rate decline, level of proteinuria, Banff score on biopsy, or 
MFI of the immunodominant DSA.80 In contrast to these 
prospective RCTs, several retrospective analyses have sug-
gested some positive effects of rituximab in multimodal 
treatment regimens together with steroids, plasmapher-
esis, and high-dose IVIG, especially on patients with vas-
cular AMR.55,62,81 A recent study developed a prognostic 
score on the basis of a treatment response to a regimen 
with Rituximab in the context of multimodal therapy. 
Moreover, a single-center nonrandomized study suggests 
that Rituximab as an add-on therapy may prevent DSA 
rebound as part of a desensitization protocol in highly 
sensitized patients.82 However, optimal doses, number 
of treatment cycles, and the effect on patients without 
a vascular component remain unclear, as is the need for 
Rituximab within a multimodal regimen.83
Imlifidase
Imlifidase (Hansa Biopharma AB), an IgG-degrading 
enzyme of Streptococcus pyogenes (IdeS), can rapidly 
reduce or even eliminate anti-HLA DSA and is undergo-
ing clinical trials in AMR.84 IdeS cleaves human IgG at a 
highly specific amino acid sequence within the hinge region 
producing Fc and F(ab)2 fragments and effectively block-
ing CDC and antibody-dependent cellular cytotoxicity.85 
Although data are lacking for using IdeS in AMR, this 
agent has been used safely in highly sensitized individuals 
for desensitization. After administration of IdeS, all previ-
ously positive crossmatches became negative and all stud-
ied patients received a transplant.86 Unfortunately within 
7–10 days of administration, patients often experience a 
rebound in DSA and anti-IdeS antibodies develop after 1 
or 2 doses, thereby preventing repeated administrations. 
Thus, IdeS will unlikely be an isolated treatment for active 
or chronic active AMR, but rather an adjunct to other ther-
apies aiming to reduce DSA in the long term. The unique 
feature of this drug is that it permits any highly sensitized 
patient to undergo transplantation within hours of a donor 
being identified regardless of the crossmatch status.
Antithymocyte Globulin
Since its introduction, antithymocyte globulin (ATG) 
or other T-cell–depleting antibodies have been used for 
treatment of refractory rejection, vascular rejection, mixed 
rejections, and AMR.69,87 Although depleting antibodies 
were proposed by KDIGO guidelines as potential treatment 
options,56 no benefit has been demonstrated for treatment 
of pure AMR with T-cell–depleting therapy.55,62,87 No pro-
spective trial with ATG for AMR had been performed, and 
a large retrospective series suggests that T-cell depletion in 
combination with steroids has no effect on the outcome 
in vascular AMR.81 Side effects are well described with 
a higher risk of infectious-associated death, particularly 
when ATG was combined with B-cell depletion.88
Splenectomy
There are several case series of surgical splenectomy, 
splenic embolization, and splenic radiation being used as a 
salvage procedure for severe early AMR.89,90 It must be per-
formed rapidly after the onset of early AMR to be effective. 
Designing a proper study would be challenging and patients 
who have undergone splenectomy are known to be sensi-
tized, have preformed antibody, or have undergone desen-
sitization therapy. Most of these AMR cases occur in the 
first week after transplantation and result in profound graft 
dysfunction and a sudden rise in DSA strength, usually from 
an anamnestic response. Some patients who recover develop 
transplant glomerulopathy and premature graft loss.
Proteasome Inhibitor: Bortezomib
Bortezomib is a proteasome inhibitor approved for 
the treatment of multiple myeloma that directly targets 
antibody-producing plasma cells making it an attractive 
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candidate for the treatment of active AMR.91 Data sup-
porting its use are limited to case series suggesting a posi-
tive effect within a multimodal treatment regimen of 
PLEX, IVIG, steroids, and depleting antibodies.55,62,91 The 
only prospective randomized, double-blind, placebo-con-
trolled trial was in “late” AMR and did not demonstrate 
any beneficial effect of bortezomib alone.92 The drug has 
well-documented side effects, and at the present time, there 
are no trial data to support its use.93
Cyclophosphamide
Cyclophosphamide is used for the treatment of antibody-
mediated diseases such as anti-neutrophil cytoplasmic anti-
body vasculitis or lupus nephritis. Previous anecdotal reports 
describe its use within a multimodal treatment regimen for 
the treatment of refractory rejections.62,94 While it is rela-
tively inexpensive, there are no trial data to support its use.
Interleukin-6 Inhibitors
A single-center, nonrandomized trial of tocilizumab 
(anti-interleukin-6 receptor monoclonal antibody) was 
undertaken in 36 patients with chronic active AMR that 
had failed IVIG plus rituximab. Patient and graft survival 
at 6 years (91% and 80%, respectively) were found to be 
superior to historical controls, with significant reductions 
in DSA and stabilization of renal function.95 Partly based 
on these encouraging results, a small investigator-initiated 
randomized control trial has begun recruitment and a large 
multicenter randomized control trial has been initiated to 
evaluate Clazakizumab, an anti-interleukin-6 monoclonal 
antibody, for the treatment of chronic active AMR.96
CONSENSUS FOR TREATMENT OF EARLY ACTIVE 
AMR (≤30 DAYS POSTTRANSPLANT)
The current evidence for treatment options in active 
AMR is of limited quality. The consensus view was that 
the combination of PLEX, IVIG with corticosteroids could 
be regarded as standard of care, consistent with the con-
clusions of the FDA workshop and KDIGO guidelines 
(Table 4).6,56 However, in some centers, the use of corticos-
teroids is reserved for patients with concompetant TCMR. 
While adjunctive therapy with other agents has been used 
in specific settings, there have been only 3 (underpow-
ered) prospective randomized trials for treatment of active 
AMR.78,79,92 These trials had many limitations, and most 
evidence comes from small retrospective studies with dif-
ferent combination therapies using different AMR defini-
tions in different populations.40,55,62,83 Thus, the available 
evidence supporting the use of any adjunctive agents is of 
low quality with the best evidence relating to drug toxicity 
and costs. Nevertheless, these rejections are relatively rare 
with a high incidence of graft loss and a randomized clini-
cal trial would be difficult to achieve. Hence, in the absence 
of trial data, the consensus was that adjunctive therapy 
may be warranted especially when the risk of graft loss 
is considered high. The recommended adjunctive therapies 
include complement inhibitors, rituximab, or splenectomy 
depending on availability (Table  4). Where concomitant 
TCMR is present, it should be treated.
CONSENSUS FOR TREATMENT OF LATE 
ACTIVE AND CHRONIC ACTIVE AMR (≥30 DAYS 
POSTTRANSPLANT)
Preexisting DSA
As described above, the transition from active to chronic 
active AMR should be considered a continuum, and the 
DSA may have been present at the time of transplant or 
appear de novo. Among patients with known preexisting 
DSA and active AMR without chronic features, the con-
sensus treatment recommendations include PLEX, IVIG, 
and corticosteroids.
TABLE 4.
Consensus treatment recommendations based on available evidence and expert opinion
Timing DSA
Histology 
(Banff 2017) Standard of carea
Consider adjunctive  
therapies
Earlya Acute  
(<30 days 
posttransplant)
Preexisting DSA (or 
nonimmunologi-
cally naive)
Active AMR Plasmapheresis (daily or alternative day × 6 based on 
DSA titer) (1C)b
IVIG 100 mg/kg after each plasmapheresis treatment or 
IVIG 2 g/kg at end of plasmapheresis treatments (1C)
Corticosteroids (EO)
Complement inhibitors (2B)
Rituximab 375 mg/m2 (2B)
Splenectomy (3C)
Late (>30 days 
posttransplant)
Preexisting DSA Active AMR Plasmapheresis (daily or alternative day × 4–6 based on 
DSA titer) (2C)b
IVIG 100 mg/kg after each plasmapheresis treatment or 
IVIG 2 g/kg at end of plasmapheresis treatments (2C)
Corticosteroids (EO)
Rituximab 375 mg/m2 (2B)
  Chronic AMR Optimize baseline immunosuppression (eg, add steroids if 
on a steroid-free regimen) (1C)
IVIG (3C)
 De novo DSA Active AMR Optimize baseline immunosuppression (eg, add steroids if 
on a steroid-free regimen) (1C)
Evaluate and manage nonadherence
Plasmapheresis and IVIG (3C)
Rituximab (3C)
  Chronic AMR  IVIG (3C)
aFor all cases, treatment of concomitant T-cell–mediated rejection (≥borderline) and optimizing immunosuppression is recommended. Optimizing immunosuppression includes the use of tacrolimus 
with goal trough of >5 and use of maintenance steroid equivalent to prednisone 5 mg daily.
bFresh-frozen plasma to be used for replacement fluid for plasmapheresis if a biopsy was performed within 24–48 h. The codes for grades of evidence have been taken from KDIGO.54,56
AMR, antibody-mediated rejection; DSA, donor-specific antibody; EO, expert opinion; IVIG, intravenous immune globulins; KDIGO, Kidney Disease: Improving Global Outcomes.
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In cases of chronic active AMR or chronic transplant 
vasculopathy, goals of therapy should be to stabilize or 
reduce the rate of decline in GFR, proteinuria, histological 
injury score, and titer of DSA while minimizing drug toxic-
ity. The use of IVIG and PLEX, with or without Rituximab, 
has not been shown to improve outcomes in patients with 
chronic active AMR (as distinct from acute active AMR) 
and has to be balanced against increased risk of adverse 
events such as infection and cost. The consensus opinion 
was that treatment should focus on optimizing immuno-
suppression and supportive care, with reintroduction of 
steroids (if on a steroid-free regimen), maintaining trough 
tacrolimus levels >5 ng/mL, and  optimizing medical man-
agement with focus on blood pressure, blood glucose, and 
lipid control.
De Novo DSA
dnDSA generally occurs in the context of reduced immu-
nosuppression whether from patient nonadherence or a 
physician-directed change in immunosuppression. AMR in 
this setting is also often initially detected with concomi-
tant TCMR. Therefore, the standard for managing AMR 
in this setting (active or chronic active) is to optimize base-
line immunosuppression and manage potential medica-
tion nonadherence. Treatment of concomitant TCMR is 
recommended in all cases of AMR but is particularly rel-
evant in these cases. Similar to patients with chronic active 
AMR in the context of preexisting antibodies, treatment 
with PLEX, IVIG, and Rituximab is used in some centers, 
although the evidence level (3C) is low.
CONCLUSIONS
Despite the severity of the problem and poor outcomes 
for patients who develop AMR, there is very little high-
level evidence to support the use of any therapy. Most 
trials in this area have been small investigator-initiated 
studies with small numbers of participants, lacking appro-
priate controls. As a result, there were no clear treatment 
regimens to recommend and there are no approved treat-
ments. The consensus opinion of those present at the meet-
ing was based largely on observational studies, low-level 
evidence, and expert opinion. Despite the clear lack of evi-
dence, it was considered important to define a standard of 
care for AMR, which could be used as a benchmark for 
future studies and prospective trials. It is obvious that new 
agents and clinical trials are needed urgently. Future direc-
tions in this field will require new trial designs and large 
transnational trial consortia to undertake these studies.97 
In addition, better characterization of the different forms 
of AMR based on pathophysiology, histology, as well as 
clinical and genetic phenotypes is needed.
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